Cell Immunotherapy Concept Rises 5.98%; Main Capital Inflow Reaches RMB 2.427 Billion
The cell immunotherapy concept sector rose 5.98% on August 7, ranking fourth among concept sectors, with 62 stocks advancing and several hitting 20% limit-up. Main capital inflows reached RMB 2.427 billion, with Hengrui Medicine leading at RMB 1.103 billion. Yinasi, Heyuan, and Puruisi gained 16.45%, 15.89%, and 14.65%, respectively. The sector outpaced most peers, while CRO concept led gains at 8.05%.
As of the close on August 7, the cell immunotherapy concept sector rose 5.98% overall, ranking fourth among concept sectors. Within the sector, 62 stocks advanced, with Boteng, Jinan, and Baipusai hitting 20% limit-up, while Baihua Pharma and Zhaoyan New Drug also hit limit-up. Yinasi, Heyuan, and Puruisi led the gains, rising 16.45%, 15.89%, and 14.65%, respectively. The decliners included ST Baling and Xuerong Bio, which fell 1.6% and 0.75%, respectively. On the day's concept sector gainers list, CRO concept rose 8.05% to lead, weight-loss drugs rose 6.62%, recombinant protein rose 6.61%, cell immunotherapy rose 5.98%, PET copper foil rose 5.55%, innovative drugs rose 4.86%, PCB concept rose 4.73%, and Alzheimer's concept rose 4.37%. On the losing side, Tianjin Free Trade Zone fell 1.98%, shared bikes fell 1.92%, cross-border payment (CIPS) fell 1.82%, and digital currency fell 1.70%. In terms of capital flows, the cell immunotherapy concept sector recorded a net main capital inflow of RMB 2.427 billion on the day, with 43 stocks seeing net inflows, and 5 stocks with net inflows exceeding RMB 100 million. Hengrui Medicine led with a net main capital inflow of RMB 1.103 billion, followed by Zhaoyan New Drug with RMB 324 million, Yiqiao with RMB 219 million, and Boteng with RMB 148 million. In terms of net inflow ratio, Yiqiao, Hengrui, and Jinan had net inflow ratios of 16.01%, 14.52%, and 13.46%, respectively, leading the rankings.